Could a vitamin B3 pill protect the brain's blood vessels in Parkinson's?

NCT ID NCT07703137

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This trial investigates whether nicotinamide riboside (NR), a form of vitamin B3, can improve blood vessel health in the brain, memory, and physical function in people with Parkinson's disease. Participants are randomly assigned to take either NR or a placebo daily for 12 weeks. Researchers measure changes in brain blood flow, cognitive test scores, and physical performance to see if NR offers any benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nicotinamide riboside (a form of vitamin B3)
What this could lead to
If it works, this could point toward a simple dietary supplement that helps preserve brain blood vessel function and slow cognitive or physical decline in Parkinson's disease.
What could go wrong
This is a small, early-stage trial with only 40 participants, so results may not apply broadly. The supplement may show no benefit over placebo, and long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Center for Geroscience and Healthy Brain Aging

    Oklahoma City, Oklahoma, 73117, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.